AI Insights
The AI conversation is currently dominated by Large Language Models, but an exclusive focus on these generalist systems risks overlooking the true next frontier of enterprise AI.
The idea that AI will simply replace human doctors in diagnosis misses the point entirely. A better future doesn’t automate the diagnostic process; it fundamentally redefines the role of human expertise within it.
The biggest risk for enterprises adopting AI today isn’t a lack of proprietary data or compute power; it’s the misguided belief that true competitive advantage only comes from closed-source, bespoke models.
Most financial institutions believe AI’s greatest value lies in predicting market direction or identifying broad economic trends.
AI and Drug Discovery: How Machine Learning Is Accelerating Medicine Most discussions around AI in drug discovery miss the point: this isn’t merely about accelerating existing processes.
AI isn’t merely accelerating scientific discovery; it’s fundamentally altering how scientists think and operate, pushing traditional human intuition to a secondary role in some domains.
If you still view artificial intelligence as a separate product feature or a grand, standalone system, you’re missing the quiet revolution already underway.
AI isn’t just changing how we process language; it’s fundamentally reshaping the nature of language itself, a claim most linguists would initially dismiss.
Most enterprises investing in augmented and mixed reality today are fixated on hardware specs and immersive graphics. They’re missing the point: the true competitive advantage in spatial computing isn’t visual fidelity; it’s intelligence.
The biggest misconception in B2B sales and marketing isn’t about what AI can do, but who it’s for. Most executives still see AI as a support function, a tool for the junior team, when in reality, it’s becoming the most potent strategic partner for leadership.
